Free Trial Information
BioCentury | Jan 9, 2021
Finance

Closing year with flurry of deals, Tordjman’s Jeito fine-tunes its investment strategy

...— gave it a second strategic partner after WuXi AppTec...
Read More
BioCentury | Dec 15, 2020
Deals

Hillhouse’s Overland builds momentum with second marquee China deal with Allogene

...and later president of Simcere’s U.S. unit; and WuXi AppTec...
Read More
BioCentury | Dec 15, 2020
Deals

ADC Therapeutics caps year of milestones by building bridge to China via Hillhouse-backed Overland’s debut deal

...a CRO; Genor Biopharma Co. Ltd. (HKEX:6998) and WuXi AppTec...
...and later president of Simcere’s U.S. unit; and WuXi AppTec...
Read More
BioCentury | Dec 9, 2020
Emerging Company Profile

How D3 Bio is building its biomarker-driven pipeline

...Partners China, Sequoia Capital China, Temasek, and WuXi AppTec’s...
...seek additional funds sooner to support in-licensing deals. WuXi AppTec...
...Partners China, Sequoia Capital China, Temasek, and WuXi AppTec’s...
Read More
BioCentury | Nov 20, 2020
Deals

China in-licensing play LianBio follows $310M crossover round with broad Pfizer deal

...cross-border healthcare investment banking for China Renaissance, managing director at Labrador Advisors and VP of strategy at WuXi AppTec...
Read More
BioCentury | Nov 17, 2020
Finance

D3 Bio’s debut with $200M series A highlights China’s fast-track to global stage

...a syndicate of investors including Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec’s...
Read More
BioCentury | Nov 14, 2020
Finance

Jeito adds dry powder to invest in European innovation

...Europe, CEO Paul Hudson said in a statement.WuXi AppTec...
Read More
BioCentury | Nov 13, 2020
Emerging Company Profile

Kira: overcoming the complexities of complement

...translational therapeutics, and Pan was VP of operation and head of program management office at WuXi AppTec...
Read More
BioCentury | Nov 3, 2020
Finance

Nov. 3 Quick Takes: JW lists in Hong Kong; plus Fountain Healthcare’s €125M fund, and EMA reviewing GenSight, Vifor/ChemoCentryx programs

...billion ($300 million) in an IPO. Bristol Myers Squibb Co. (NYSE:BMY) subsidiary Juno Therapeutics and WuXi AppTec...
Read More
BioCentury | Oct 29, 2020
Finance

Perceptive-backed in-licensing play LianBio to cast a wide net with $310M crossover round

...Labrador Advisors and VP of strategy at WuXi AppTec...
Read More
Items per page:
1 - 10 of 161
BioCentury | Jan 9, 2021
Finance

Closing year with flurry of deals, Tordjman’s Jeito fine-tunes its investment strategy

...— gave it a second strategic partner after WuXi AppTec...
Read More
BioCentury | Dec 15, 2020
Deals

Hillhouse’s Overland builds momentum with second marquee China deal with Allogene

...and later president of Simcere’s U.S. unit; and WuXi AppTec...
Read More
BioCentury | Dec 15, 2020
Deals

ADC Therapeutics caps year of milestones by building bridge to China via Hillhouse-backed Overland’s debut deal

...a CRO; Genor Biopharma Co. Ltd. (HKEX:6998) and WuXi AppTec...
...and later president of Simcere’s U.S. unit; and WuXi AppTec...
Read More
BioCentury | Dec 9, 2020
Emerging Company Profile

How D3 Bio is building its biomarker-driven pipeline

...Partners China, Sequoia Capital China, Temasek, and WuXi AppTec’s...
...seek additional funds sooner to support in-licensing deals. WuXi AppTec...
...Partners China, Sequoia Capital China, Temasek, and WuXi AppTec’s...
Read More
BioCentury | Nov 20, 2020
Deals

China in-licensing play LianBio follows $310M crossover round with broad Pfizer deal

...cross-border healthcare investment banking for China Renaissance, managing director at Labrador Advisors and VP of strategy at WuXi AppTec...
Read More
BioCentury | Nov 17, 2020
Finance

D3 Bio’s debut with $200M series A highlights China’s fast-track to global stage

...a syndicate of investors including Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec’s...
Read More
BioCentury | Nov 14, 2020
Finance

Jeito adds dry powder to invest in European innovation

...Europe, CEO Paul Hudson said in a statement.WuXi AppTec...
Read More
BioCentury | Nov 13, 2020
Emerging Company Profile

Kira: overcoming the complexities of complement

...translational therapeutics, and Pan was VP of operation and head of program management office at WuXi AppTec...
Read More
BioCentury | Nov 3, 2020
Finance

Nov. 3 Quick Takes: JW lists in Hong Kong; plus Fountain Healthcare’s €125M fund, and EMA reviewing GenSight, Vifor/ChemoCentryx programs

...billion ($300 million) in an IPO. Bristol Myers Squibb Co. (NYSE:BMY) subsidiary Juno Therapeutics and WuXi AppTec...
Read More
BioCentury | Oct 29, 2020
Finance

Perceptive-backed in-licensing play LianBio to cast a wide net with $310M crossover round

...Labrador Advisors and VP of strategy at WuXi AppTec...
Read More
Items per page:
1 - 10 of 161